Description of the inflammatory bowel disease natural history in Tehran province, Iran: Mixed panel approaches
Gastroenterology and Hepatology from Bed to Bench,
Vol. 14 No. Supplement 1 (2021),
30 December 2021
https://doi.org/10.22037/ghfbb.vi.2354
Abstract
Aim: Description of the inflammatory bowel disease natural history in Tehran province.
Background: Inflammatory bowel disease (IBD) is a non-homogeneous disorder with an unpredictable natural history that impairs a patient's quality of life over the course of their life. As a result, providing evidence for efficient patient management is critical.
Methods: In this case series study, 198 IBD patients who were visited in our clinic at least three times routinely from Oct 2015 to May 2020 were included. Then, two panel-based approaches, the Multi-State Model (MSM) and random-effect ordered logistic, were used to deduce the clinical course of IBD, which included remission, mild, moderate to severe, and surgical states.
Results For ulcerative colitis (UC), women had a slightly poorer condition for remission but better for moderate to severe and a faster transition from moderate to severe to mild (HR=1.490, 95% CI: 1.02-2.16) compared to men. For Crohn's disease (CD), they had a better condition for remission but a slightly poorer condition for the severe state and higher transition from mild to moderate to severe (HR=1.221, 95% CI: 0.471-3.22) than men. Oral 5-ASA had better efficacy in people with remission and/or mild states but not for those with moderate to severe states, especially in CD (mild to moderate to serve, HR=1.526, 95% CI: 0.59-3.89). Immunosuppressive drugs were better for patients with lower disease severity, especially with UC (mild to remission, HR=1.258, 95% CI: 0.75-2.09).
Conclusion: Panel approaches have the potential efficacy to tackle the unpredictable clinical course of IBD (UC/CD). Hence, we highly recommend that our findings be included into the Iranian routine clinical environment of IBD and/or that related studies be conducted in Iran and other regions to gain a better understanding of the natural history of IBD.
- Inflammatory Bowel Disease; Multi-state model; Panel data; Crohn's disease; Ulcerative colitis
How to Cite
References
2. Zaharie R, Zaharie F. Inflammatory Bowel Diseases: Epidemiology and Natural History. 2018.
3. Weimers P, Munkholm P. The natural history of IBD: lessons learned. Current treatment options in gastroenterology. 2018;16(1):101-11.
4. Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol. 2016;22(3):1017-33.
5. Beck JR. Markov models of natural history. Journal of clinical epidemiology. 1988;41(7):619-21.
6. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Medical decision making : an international journal of the Society for Medical Decision Making. 1993;13(4):322-38.
7. Christopher H. Jackson. Multi-State Models for Panel Data: The msm Package for R. Journal of Statistical Software. 2011;38(8):1-29.
8. Le-Rademacher JG, Peterson RA, Therneau TM, Sanford BL, Stone RM, Mandrekar SJ. Application of multi-state models in cancer clinical trials. Clin Trials. 2018;15(5):489-98.
9. Gasperoni F, Ieva F, Barbati G, Scagnetto A, Iorio A, Sinagra G, et al. Multi-state modelling of heart failure care path: A population-based investigation from Italy. PLOS ONE. 2017;12(6):e0179176.
10. Ashton JJ, Mossotto E, Ennis S, Beattie RM. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019;8(1):56-69.
11. Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, et al. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. The American journal of gastroenterology. 2018;113(8):1197-205.
12. Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, et al. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2019;68(6):977-84.
13. Blumenstein I, Herrmann E, Filmann N, Zosel C, Tacke W, Bock H, et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: A subgroup analysis of a large multi-centre, prospective, internet-based study. Journal of Crohn's and Colitis. 2011;5(3):203-10.
14. Bokemeyer B, Hardt J, Hüppe D, Prenzler A, Conrad S, Düffelmeyer M, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. Journal of Crohn's & colitis. 2013;7(5):355-68.
15. Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg. 2016;8(5):363-70.
16. Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res. 2019;8:F1000 Faculty Rev-210.
17. Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterology Report. 2019;7(2):77-90.
18. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. The American journal of gastroenterology. 2004;99(7):1371-85.
19. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. The American journal of gastroenterology. 2005;100(11):2478-85.
20. Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55 Suppl 1(Suppl 1):i16-35.
21. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews. 2002(4):Cd000544.
22. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. The Cochrane database of systematic reviews. 2005(1):Cd003715.
23. Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4(4):237-48.
24. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. The New England journal of medicine. 2010;362(15):1383-95.
25. Panccione R, Ghosh S, Middleton S, Marquez JR, Khalif I, Flint L, et al. Infliximab, azathioprine, or infliximab+ azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. 2011;140(5):S-134.
26. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Official journal of the American College of Gastroenterology | ACG. 2018;113(4).
27. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Official journal of the American College of Gastroenterology | ACG. 2019;114(3).
- Abstract Viewed: 59 times
- pdf Downloaded: 31 times